In this Review:
Stopping TKIs in CML: EURO-SKI
Persistent driver mutations during CR contribute to inferior outcomes in elderly AML
Blinatumomab in relapsed/refractory Ph– B-cell precursor ALL: TOWER
Long-term outcomes with ruxolitinib in myelofibrosis: COMFORT-I
Molecular profile and acute myeloid transformation risk in PV/ET
Ruxolitinib in PV with nonpalpable spleen: RESPONSE-2
Long-term follow-up of early-stage HL: updated GHSG trials
Early rituximab intensification with R-CHOP14 in DLBCL
CUDC-907 (dual HDAC/PI3K inhibitor) in relapsed/refractory DLBCL
High-dose chemotherapy and SCT in primary CNS lymphoma with preserved cognition
Please login below to download this issue (PDF)